| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aldeyra Therapeutics, Inc.$2.07
-0.21 (-9.34%)
C 53Pipeline Score Undervalued Biotech · Clinical
Market Cap
98.93 M
EPS
-0.46
P/E Ratio
-3.6 $
Value Trade
3.54 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.41 M
Operating CF
-5.11 M
Total Assets
66.48 M
Total Liabilities
24.33 M
Equity
42.16 M
D/E Ratio
12,345
-4.91 %
Week
-7.74 %
1 Month
-69.12 %
3 Month
-67.09 %
6 Month
-86.96 %
5 Year
-79.33 %
All Time
Cash Data
Cash Position
65.00 M
Monthly Burn
1.70 M
Runway
36.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.23 M
52 Week Range
1.07 - 6.18
% held by Insiders
3.7 %
% held by Institutions
62.07 %
Enterprise Value
49.44 M
Total Shares
60.18 M
Short %
11.47 %
Float Shares
49.47 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aldeyra Therapeutics, Inc.
463Total events
1Upcoming
162Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 1
Event history 462
Jun 10, 2026
Jun 9, 2026
Apr 16, 2026
◆Type A MeetingreproxalapFDA Meeting
Aldeyra intends to request Type A meeting with FDA to discuss NDA approval path
dry eye diseasesource ↗
Mar 17, 2026
▼Complete Response LetterreproxalapFDA Decision
FDA issued Complete Response Letter for reproxalap NDA for dry eye disease
dry eye diseasesource ↗
Mar 16, 2026
◆PDUFA DatereproxalapRegulatory Filing
PDUFA target action date extended to March 16, 2026
dry eye diseasesource ↗
Feb 25, 2026
◆Oral PresentationPresentation
Aldeyra to participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference fireside chat
2026
◆Trial CompletionADX-2191Trial
Clinical trial expected to conclude in 2026
primary vitreoretinal lymphomasource ↗
2026
●IND SubmissionADX-248IND
IND filing for ADX-248 anticipated in 2026
metabolic inflammation (obesity, hypertriglyceridemia)source ↗
2026
●IND SubmissionADX-246IND
IND filing for ADX-246 anticipated in 2026
dry age-related macular degenerationsource ↗
Dec 17, 2025
◆PDUFA DatereproxalapRegulatory Filing
PDUFA target action date for NDA resubmission (6 months from submission)
dry eye diseasesource ↗
Dec 16, 2025
◆PDUFA DatereproxalapRegulatory Filing
PDUFA target action date set for reproxalap NDA
dry eye diseasesource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $869M
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored8.8x
rNPV / MCap Top 81%
Micro Cap (rank 174 of 911)
Percentile RankAldeyra Therapeutics, Inc. carries a moderate pipeline score (53/100), with $3.5B risk-adjusted pipeline value, led by ADX-629 in Plaque Psoriasis (Phase 2), across $93B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX-629 Small molecule | Alcohol Hepatitis | Phase 2 | NCT06685692 | 21% | $1.2B | COMPLETED | 4 | - | - | Jun 18, 2025 | - | MEDIUM Jul 4, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ADX-629 | alcohol-associated hepatitis | Phase 2 | 2025-10-28 | MELD score: P=0.001; triglyceride levels: P<0.0001; C Reactive Protein: P<0.0001 Read More | candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabiliti Read More | |
ADX-629 | alcohol-associated hepatitis | Phase 2 | 2025-10-28 | MELD score: P=0.001; triglyceride levels: P<0.0001; C Reactive Protein: P<0.0001 Read More | candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabiliti Read More | |
ADX-629 | alcohol-associated hepatitis | Phase 2 | 2025-10-28 | MELD score: P=0.001; triglyceride levels: P<0.0001; C Reactive Protein: P<0.0001 Read More | candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabiliti Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALDXAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its Board of Directors. This move is part of the company's ongoing efforts to strengthen its leadership team. Details regarding her background and the implications of this appointment have not been disclosed in the article.
Read more →ALDXexpectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilities and strategy; Aldey
Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board of directors. With over 30 years of experience in biotechnology, she is expected to enhance Aldeyra's strategy towards the commercialization of innovative therapies aimed at immune-mediated diseases. Her previous roles include acting Chief Financial Officer at Normunity Inc. and Chief Financial Officer at F-star Therapeutics. Aldeyra is focused on developing pharmaceuticals that modulate protein systems to treat unmet medical needs.
Read more →ALDXAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics is set to participate in the 2026 Jefferies Global Healthcare Conference. This event will provide a platform for the company to discuss its developments and future plans. Details regarding the specific topics to be addressed during the conference have not been disclosed.
Read more →ALDXALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is reminding investors in Aldeyra Therapeutics, Inc. of a securities class action lawsuit deadline on May 29, 2026. The lawsuit, which has already been filed, claims that the company made false statements regarding the efficacy of its clinical trials for reproxalap. As a result, investors may be eligible for compensation due to the misleading information. Potential plaintiffs are encouraged to seek counsel with proven litigation experience as they consider their options.
Read more →ALDX▲ +14.8%on this newsshared move
ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
A class action lawsuit has been initiated against Aldeyra Therapeutics, alleging that the company made false and misleading statements regarding its business and clinical trial results. The lawsuit pertains to securities bought between November 3, 2023, and March 16, 2026, with a deadline for investor participation set for May 29, 2026. Key allegations include the inconsistency of results from clinical trials for reproxalap, which have rendered any positive findings questionable. Investors are encouraged to discuss their options with the law firm representing the case.
Read more →ALDX▼ -70.7%on this news
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Aldeyra Therapeutics has received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, intended for treating dry eye disease. The FDA cited insufficient evidence of efficacy from clinical trials and expressed concerns about the reliability of positive findings. Aldeyra plans to request a Type A meeting to discuss the next steps for potential approval.
Read more →ALDX▼ -70.7%on this news
future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; updated or refined data based on Aldeyra's continuing or post-hoc review and quali
Aldeyra Therapeutics announced that it has received a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application (NDA) regarding reproxalap, indicating a lack of substantial evidence of the drug's efficacy for treating dry eye disease. The FDA raised concerns about the reliability of study results and noted that the totality of evidence did not support the product's effectiveness. Aldeyra plans to request a Type A meeting with the FDA to discuss possible next steps and has sufficient funding to maintain operations until 2028.
Read more →ALDX▼ -70.7%on this news
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Aldeyra Therapeutics is under investigation by Johnson Fistel, PLLP for potential claims regarding losses incurred by investors after the FDA declined to approve the company's lead drug reproxalap for dry eye disease. The FDA's decision was based on insufficient efficacy evidence, leading to a significant drop in the company's stock price, which fell by more than 70% on the announcement date. Johnson Fistel's inquiry aims to determine if Aldeyra Therapeutics violated federal securities laws, impacting investor rights and potential recoveries.
Read more →ALDXAldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics announced that its CEO, Dr. Todd C. Brady, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The event is scheduled for February 25, 2026, at 10:40 a.m. ET. The discussion will be available for live viewing and archived for 90 days on Aldeyra's website.
Read more →ALDX▲ +33.1%on this news
indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra's ability to commercialize (alone or with others) and obtain reimbursement
Aldeyra Therapeutics announced that the FDA has extended the PDUFA target action date for its New Drug Application (NDA) for reproxalap, aimed at treating dry eye disease, to March 16, 2026. This extension follows the acceptance of the NDA, which was completed on July 16, 2025. However, the drug's field trial did not meet its primary endpoint, raising questions about future commercial viability. Aldeyra submitted additional data to address FDA requests, and a response to the draft label has been provided, with further communications expected by February 16, 2026.
Read more →ALDX▼ -5.3%on this news
Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act o
Aldeyra Therapeutics presented an overview of its research and development plans, highlighting its pipeline of potential therapies targeting immune-mediated diseases. The company identified multiple forward-looking statements, emphasizing the uncertainties regarding the outcomes of clinical trials and regulatory approvals. They reported a cash position of $75.3 million, expected to sustain operations through the second half of 2027. Aldeyra also acknowledged potential risks that could affect its development timelines and overall performance.
Read more →ALDXcandidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabiliti
Aldeyra Therapeutics announced positive results from its Phase 2 clinical trial for ADX-629, a signal-finding RASP modulator, which demonstrated significant improvements in liver function in patients with alcohol-associated hepatitis. The company has shifted its pipeline focus to next-generation RASP modulators ADX-248 and ADX-246 for various immune-mediated diseases. Aldeyra also reported that its cash runway is extended into the second half of 2027, ensuring operational stability amidst clinical developments, although ADX-629's clinical development has been discontinued pending further investigations. The outcomes of regulatory submissions and market acceptance remain critical factors for Aldeyra's future growth.
Read more →ALDXAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease PDUFA Target Action Date
Aldeyra Therapeutics announced that the FDA has accepted the resubmission of its New Drug Application for reproxalap, aimed at treating dry eye disease. The FDA has set a target action date of December 16, 2025. Reproxalap is notable for achieving the primary endpoint in clinical trials. However, the FDA mandated further clinical trials to validate efficacy.
Read more →ALDX▲ +10.3%on this news
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Lexington, Mass.
Aldeyra Therapeutics announced that it has received a Special Protocol Assessment Agreement Letter from the FDA for its investigational drug ADX-2191, aimed at treating primary vitreoretinal lymphoma. The drug, a new formulation of methotrexate designed for intraocular injection, currently lacks FDA-approved therapies. Following a prior Complete Response Letter, it is now set to undergo a clinical trial comparing treatment efficacy between a single injection and multiple injections. The trial is expected to commence in the latter half of 2025 and conclude by 2026.
Read more →ALDXAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Lexington, Mass.
Aldeyra Therapeutics has resubmitted its New Drug Application for reproxalap to the FDA for the treatment of dry eye disease. The submission includes data from a recently completed clinical trial that met its primary endpoint, addressing previous concerns from the FDA. The company remains hopeful as there were no significant safety issues reported in the trials. This resubmission marks a vital step for Aldeyra in progressing reproxalap toward potential approval.
Read more →ALDX▼ -22.2%on this news
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman
Aldeyra Therapeutics, Inc. (ALDX) faced significant investor backlash after its stock price plummeted by over 70% following an FDA Complete Response Letter regarding the New Drug Application for reproxalap. The FDA's letter indicated that the drug's efficacy had not been adequately demonstrated, necessitating at least one additional well-controlled study. This situation led to an investigation by the Hagens Berman law firm, focusing on potential misrepresentation of the drug's approval prospects by Aldeyra.
Read more →ALDX▲ +9%on this news· ran to +20% by day 3shared move
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors Lexington, Mass.
Aldeyra Therapeutics has appointed Chip Clark to its Board of Directors, enhancing its leadership team with his extensive experience in the biopharmaceutical sector. Currently the CEO of Vibrant Biomedicines, Clark's background includes key roles at Genocea Biosciences and Vanda Pharmaceuticals. His expertise is expected to support Aldeyra's mission to advance innovative therapies addressing significant medical needs. Aldeyra's diversified pipeline targets immune-mediated and metabolic diseases, with key product candidates in late-stage development.
Read more →ALDXALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Aldeyra Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has initiated an investigation into Aldeyra Therapeutics, Inc. on behalf of stockholders amid concerns of potential violations of federal securities laws. This follows Aldeyra's announcement of a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, which was not deemed effective for treating dry eye disease. The FDA highlighted issues with the trial data and recommended further studies to demonstrate efficacy. As a result, Aldeyra's stock price declined significantly.
Read more →ALDX▼ -73.3%on this news
C O N F E R E N C E C A L L Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update
Aldeyra Therapeutics received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, citing insufficient evidence of efficacy in treating dry eye symptoms. The letter indicates that further studies are needed to provide the necessary data for resubmission. With ongoing trials expected to yield results soon, Aldeyra is positioned to pursue potential resubmission, backed by a strong cash position. The regulatory landscape remains flexible, with timelines subject to change based on FDA workload and other factors.
Read more →ALDX▲ +11.6%on this news
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement PDUFA Date is
Aldeyra Therapeutics announced the FDA's acceptance of the resubmitted New Drug Application for reproxalap, aimed at treating dry eye disease, with a PDUFA date set for April 2, 2025. Concurrently, Aldeyra expanded its exclusive option agreement with AbbVie, which could lead to significant financial outcomes for Aldeyra, including upfront and milestone payments. This agreement emphasizes both companies' commitment to bringing this innovative therapy to market, following encouraging results from previous trials with reproxalap showing no severe safety concerns.
Read more →ALDX▲ +28.5%on this news· ran to +56% by day 1
Dry Eye Disease Chamber Phase 3 Clinical Trial of Reproxalap
Aldeyra Therapeutics reported positive results from a Phase 3 clinical trial of reproxalap for dry eye disease, achieving its primary endpoint of reducing ocular discomfort. The trial involved 132 patients and had no significant safety issues reported, as confirmed by the treatment of over 2,500 patients previously. Aldeyra is optimistic that these results will satisfy U.S. FDA requirements for a New Drug Application resubmission, anticipated in 2024. This marks a significant step forward in the development of reproxalap as a treatment option for dry eye disease.
Read more →ALDX▼ -6.5%on this news
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable Live Webcast Scheduled to Begin at 8:00 a.m. ET Today Lexington, Mass.
Aldeyra Therapeutics has announced advancements in their RASP modulator pipeline with new preclinical data focused on obesity. This update is part of their ongoing efforts to develop therapies for immune-mediated and metabolic diseases. The company will discuss these advancements in detail during their Investor Roundtable scheduled for June 20, 2024. Leadership has expressed optimism about the potential of their product candidates and forthcoming updates throughout the year.
Read more →ALDXAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024 LEXINGTON, M
Aldeyra Therapeutics announced the completion of enrollment in its Phase 3 clinical trial for reproxalap, a treatment for dry eye disease, with 132 patients enrolled. The company expects to resubmit a New Drug Application (NDA) in the second half of 2024, contingent on positive trial results anticipated in Q3 2024. The trial aims to demonstrate improved ocular discomfort metrics compared to the vehicle control. If successful, reproxalap could feature groundbreaking labeling addressing both chronic and acute symptom improvements in dry eye patients.
Read more →ALDXR e s e a r c h & D e v e l o p m e n t D a y C O R P O A T E O A p r i l 25 , 202 4 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2024 Todd C. Brady, M.D., Ph.D., Chief Executive Officer, Aldeyra Therapeutics W e l c o m e a
Aldeyra Therapeutics recently conducted its Research and Development Day, highlighting its clinical development plans for investigational drugs including reproxalap. The presentation, led by CEO Todd C. Brady, discussed various therapeutic approaches and upcoming clinical trials, with an expected NDA resubmission for reproxalap in the second half of 2024. The event also featured insights into the company's RASP (reactive aldehyde species) modulation strategy, which presents a novel pharmacological approach. Challenges related to regulatory timelines and the predictive nature of past trial results were acknowledged.
Read more →ALDX▲ +6.2%on this news· ran to +35% by day 3
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease Lexington, Mass.
Aldeyra Therapeutics has outlined a clinical development plan for the resubmission of its New Drug Application for reproxalap, aimed at treating dry eye disease. Following consultation with the FDA, the company plans to initiate a dry eye chamber trial in the first half of 2024, with a potential resubmission of the NDA in the second half of the year, depending on the trial's results. The trial design, derived from past studies, aims to show a statistically significant improvement in ocular discomfort among participants.
Read more →ALDX▼ -6.2%on this news
Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW February 2024 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements This presentation contains forward-looking stat
Aldeyra Therapeutics, Inc. presented its Corporate Overview for February 2024, detailing its ongoing efforts in developing innovative therapies for immune-mediated diseases. The company outlined forward-looking statements regarding its clinical trials, regulatory submissions, and product pipelines, including the NDA resubmission for reproxalap. Aldeyra emphasizes its novel RASP modulation approach, while also acknowledging potential risks and uncertainties surrounding regulatory processes and trial outcomes. The company's current cash position is reported to be sufficient to fund operations into late 2025.
Read more →ALDXALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into Aldeyra Therapeutics, Inc. on behalf of long-term stockholders after a class action complaint was filed against the company. The case focuses on allegations that Aldeyra's board may have breached their fiduciary duties by providing false or misleading information regarding the effectiveness of their investigational drug ADX-2191. The FDA recently issued a Complete Response Letter for ADX-2191, citing a lack of substantial evidence to support its effectiveness, which led to a significant stock price drop. Investors are encouraged to contact the law firm for more information on the situation.
Read more →ALDXAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases Based on positive biomarker results observed in adult cohort of Phase
Aldeyra Therapeutics has reported positive advancements in its RASP platform with promising biomarker results from its Phase 2 trial of ADX-629 for Sjögren-Larsson Syndrome. The company plans to submit a proposal to include pediatric patients in this trial to the FDA in early 2024. Additionally, they have initiated a Phase 2 trial for ADX-629 in moderate alcoholic hepatitis and submitted an IND application for ADX-246 aimed at atopic dermatitis. These developments indicate significant progress in their pipeline targeting immune-mediated conditions.
Read more →ALDX▲ +18.6%on this news
Top-Line Results from thePhase 2 Clinical Trial of ADX-629in Atopic Dermatitis
Aldeyra Therapeutics announced the top-line results of its Phase 2 clinical trial for ADX-629, an investigational oral drug aimed at treating atopic dermatitis. The trial has shown promising results, indicating the potential efficacy of ADX-629, which may serve as a preferred option compared to current treatments that often involve topical corticosteroids. The data supports further exploration into reactive aldehyde species modulation in addressing various immune-mediated diseases. Given the substantial demand for safe oral therapies for atopic dermatitis, these results could enhance Aldeyra's position in the market.
Read more →ALDXC O N F E R E N C E C A L L Reproxalap for the Treatment of Dry Eye Disease Regulatory Update
Aldeyra Therapeutics provided a regulatory update on its investigational drug reproxalap for treating dry eye disease. The FDA issued a complete response letter stating that the current New Drug Application did not sufficiently demonstrate efficacy in treating ocular symptoms. As a result, Aldeyra has proposed a new symptom trial and submitted a Special Protocol Assessment to the FDA. The company anticipates that successful trial results could lead to a resubmission of their NDA in the first half of 2024.
Read more →ALDXAldeyra Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; September 29, 2023 deadline
Aldeyra Therapeutics, Inc. is facing a class action lawsuit filed by investors seeking to recover losses related to the company's securities purchased between March and June 2023. This follows the FDA's Complete Response Letter, which cited a lack of evidence for the effectiveness of ADX-2191. As a result, Aldeyra's stock price saw a significant decline of 27.4%. The suit argues that the company misrepresented the potential of ADX-2191 and did not disclose critical negative information regarding its drug application.
Read more →ALDXAldeyra Therapeutics, Inc. (ALDX) Shareholder Notice: Robbins LLP Reminds Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is facing a class action lawsuit alleging that the company misled investors about the effectiveness of its drug candidate ADX-2191. The complaint highlights that the New Drug Application submitted to the FDA lacked adequate evidence to support the drug's effectiveness. Following the FDA's issuance of a Complete Response Letter due to insufficient evidence, Aldeyra's stock price significantly decreased. Shareholders have until September 29, 2023, to file motions to act as lead plaintiffs in the class action.
Read more →ALDXTop-Line Results from thePhase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa
Aldeyra Therapeutics announced positive top-line results from its Phase 2 clinical trial of ADX-2191, an investigational treatment for retinitis pigmentosa. The study showed significant improvements in best-corrected visual acuity and retinal sensitivity, with ADX-2191 being well tolerated by participants. The drug has potential as the first approved therapy for retinitis pigmentosa, which currently has no approved treatments. A Phase 2/3 clinical trial is planned, with discussions forthcoming with regulatory authorities.
Read more →ALDXTop-Line Results from thePhase 2 Clinical Trial ofADX-629 in Chronic Cough
Aldeyra Therapeutics announced positive top-line results from its Phase 2 clinical trial of ADX-629 in patients with chronic cough. The trial showed a statistically significant reduction in cough frequency compared to placebo, with primary endpoints indicating safety was met and no safety concerns were identified. These findings contribute to the growing evidence supporting the efficacy of ADX-629, which has also shown activity in previous clinical trials across other inflammatory conditions. The results may bolster Aldeyra's ongoing development and potential regulatory filings for ADX-629.
Read more →ALDX▼ -27.4%on this news
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 Based on U.S. Food & Drug Administration (FDA) Determination of Lack of Adequate and Well Controlled Investigations in the Scientific Literature, Complete Respo
Aldeyra Therapeutics has received a Complete Response Letter from the FDA regarding its New Drug Application for ADX-2191, an investigational treatment for primary vitreoretinal lymphoma (PVRL). The FDA highlighted a lack of substantial evidence of effectiveness due to insufficient well-controlled investigations. In light of a methotrexate shortage and the absence of approved therapies for PVRL, Aldeyra is looking to discuss an Expanded Access Program with the FDA to provide potential treatment to patients. This regulatory setback comes despite the ongoing development of ADX-2191 for other retinal conditions.
Read more →ALDXTop-Line Results from thePhase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis
Aldeyra Therapeutics announced top-line results from its Phase 3 INVIGORATE-2 trial for reproxalap in treating allergic conjunctivitis. The trial successfully met all primary and secondary endpoints, showing statistically significant reductions in ocular itching and redness. Over 2,400 patients participated, with no serious safety issues reported, although mild irritation at the application site was observed. These results align with data from previous studies, indicating the drug's potential benefits for both allergic conjunctivitis and dry eye disease.
Read more →ALDXAldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Quarter of 202
Aldeyra Therapeutics has reported its financial results for the first quarter of 2023, highlighting key upcoming clinical milestones. The company anticipates top-line results from Phase 2 trials for ADX-2191 and ADX-629, as well as the Phase 3 INVIGORATE-2 trial for reproxalap, all expected in the second quarter of 2023. Financially, Aldeyra holds $165 million in cash, which is projected to fund operations into the second half of 2024. Despite a net loss of $15.6 million, the company continues to focus on developing innovative therapies for immune-mediated diseases.
Read more →ALDX▲ +7.2%on this news
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights NDA Priority Review PDUFA Date for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma is
Aldeyra Therapeutics reported its full-year 2022 financial results, highlighting a net loss of $62 million. The company announced priority review status for ADX-2191 for primary vitreoretinal lymphoma, with a PDUFA date set for June 21, 2023. Additionally, they have multiple upcoming clinical trials and results expected in 2023 for other drug candidates, including reproxalap for dry eye disease and ADX-629 for chronic cough. The management expressed optimism about the company's future due to a strong pipeline and financial position.
Read more →ALDX▲ +5.8%on this news
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma PDUFA Date is
Aldeyra Therapeutics announced that the FDA has accepted its New Drug Application for ADX-2191, designed for the treatment of primary vitreoretinal lymphoma, for Priority Review. This designation highlights the urgent need for an FDA-approved option for this rare and aggressive cancer. The FDA set a Prescription Drug User Fee Act (PDUFA) date of June 21, 2023, indicating an expedited review process. If approved, ADX-2191 could be launched in the U.S. in the latter half of 2023, pending successful regulatory review.
Read more →ALDX▲ +9.4%on this news
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease PDUFA Date is
Aldeyra Therapeutics announced that the FDA has accepted the New Drug Application for reproxalap, a potential treatment for dry eye disease, with a PDUFA date set for November 23, 2023. This first-in-class RASP modulator aims to address the needs of patients dissatisfied with existing therapies. The application is backed by significant clinical trial data demonstrating safety and efficacy. No review issues have been identified by the FDA, indicating a smooth path towards potential approval.
Read more →ALDX▲ +6.2%on this news
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX 2191 for the Treatment of Primary Vitreoretinal Lymphoma LEXINGTON, Mass.--(BUSINESS WIRE)
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX 2191 for the Treatment of Primary Vitreoretinal Lymphoma LEXINGTON, Mass.--(BUSINESS WIRE)--December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced t
Read more →ALDX▲ +10%on this news
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Primary Vitreoretinal Lymphoma New Drug Application (NDA) for ADX-2191 Expected to be Submitted as Soon as the End of 20
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Primary Vitreoretinal Lymphoma New Drug Application (NDA) for ADX-2191 Expected to be Submitted as Soon as the End of 2022 Company Intends to Request Priority Review Designation
Read more →ALDX▲ +5%on this news· ran to +25% by day 3shared move
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease LEXINGTON, Mass.--(BUSINESS WIRE)
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease LEXINGTON, Mass.--(BUSINESS WIRE)--November 29, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today an
Read more →ALDX▲ +6.2%on this news
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights New Drug Application (NDA) Submission of Reproxalap for the Treatment of Dry Eye Disease on Schedule for the Fourth Quarte
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights New Drug Application (NDA) Submission of Reproxalap for the Treatment of Dry Eye Disease on Schedule for the Fourth Quarter of 2022 Pre-NDA Meeting with the U.S. Food and Drug Admi
Read more →ALDXTop-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy October 6, 2022 NASDAQ: ALDX Aldeyra Therapeutics, Inc. 2022 2 This presentation and various remarks which may be made during this presentation contain forward-looking statem
Read more →ALDXAldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary
Read more →ALDX▲ +10.9%on this news· ran to +24% by day 3
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights Pre-NDA (New Drug Application) Meeting with the U.S. Food and Drug Administration (FDA) Scheduled for the Third Quarter o
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights Pre-NDA (New Drug Application) Meeting with the U.S. Food and Drug Administration (FDA) Scheduled for the Third Quarter of 2022 to Discuss NDA Submission of Reproxalap for the Trea
Read more →ALDX▲ +15%on this news
Top-Line Results from theDry Eye Disease Chamber Crossover Trial of Reproxalap
Top-Line Results from theDry Eye Disease Chamber Crossover Trial of Reproxalap July 12, 2022 NASDAQ: ALDX Aldeyra Therapeutics, Inc. 2022 2 This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of
Read more →ALDXAldeyra Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Aldeyra Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease June 8, 2022 NASDAQ: ALDX Aldeyra Therapeutics, Inc. 2022 Aldeyra This presentation and various remarks which may be made during this presentation contain forward-looking statements within the mea
Read more →ALDXAldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxa
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxalap Over Vehicle in Ocular Redness in Completed TRANQUILITY
Read more →ALDX▼ -6.8%on this news
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primar
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness Post-Hoc Analysis Using Comput
Read more →ALDX▼ -5.1%on this news
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected in Second Quarter of 2022 Results from
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected in Second Quarter of 2022 Results from Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative
Read more →ALDX▲ +8.3%on this news
Aldeyra Therapeutics Announces Chief Financial Officer Transition LEXINGTON, Mass.--(BUSINESS WIRE)
Aldeyra Therapeutics Announces Chief Financial Officer Transition LEXINGTON, Mass.--(BUSINESS WIRE)--April 28, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursu
Read more →ALDXWelcome and Opening Remarks Todd C. Brady, M.D., Ph.D., Chief Executive Officer
ADX-629: A First-in-Class, Oral RASP Modulator for the Treatment of Systemic Disease 2022 Research & Development Day March 29, 2022 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2022 Exhibit 99.1 Welcome and Opening Remarks Todd C. Brady, M.D., Ph.D., Chief Executive Officer March 2
Read more →ALDX▲ +16.3%on this news
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Top-Line Data from Proof-of-Concept Clinical Trials of ADX-629 in Multiple Systemic Indications Expected by the End of March 2
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Top-Line Data from Proof-of-Concept Clinical Trials of ADX-629 in Multiple Systemic Indications Expected by the End of March 2022 Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap
Read more →ALDXAldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance Top-Line Results from TRANQUILITY Expect
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance Top-Line Results from TRANQUILITY Expected This Quarter Together with Recently Completed Phase 2 C
Read more →ALDXAldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double- Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double- Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease LEXINGTON, Mass., November 2, 2021 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced
Read more →ALDX▲ +9.2%on this newsshared move
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021 Phase 2 Clinica
Read more →ALDX▲ +8.3%on this news
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease Expected in
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights LEXINGTON, Mass., August 5, 2021 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and syst
Read more →ALDXAldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights LEXINGTON, Mass., May 6, 2021 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the pote
Read more →ALDXAldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock LEXINGTON, Mass., April 27, 2021 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potenti
Read more →ALDXAldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021 Top-Line Results fro
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials Expected in the Second H
Read more →ALDXAldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock LEXINGTON, Mass., January 13, 2021 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Read more →ALDXDisclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Refor
Initial Symptom and Sign Results From Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease DATA RELEASE January 7, 2021 Nasdaq: ALDX Aldeyra Therapeutics, Inc. 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation and various remarks which may
Read more →ALDXAldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update Initiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020 Phase 2 Clinical Trials
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update LEXINGTON, Mass., November 5, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with t
Read more →ALDXAldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update Based on FDA Agreement that RASP is an Objective Sign of Dry Eye Disease, Assessment of Tear RASP Levels in Dry Eye Disea
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update LEXINGTON, Mass., August 6, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with th
Read more →ALDXAldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners Gross Proceeds of Approximately $19.5 Million from At-the-Market Offering Program Sufficient to Extend Operations Through the End of
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners Gross Proceeds of Approximately $19.5 Million from At-the-Market Offering Program Sufficient Operations Through the End of 2022, Including Potential New Drug Application (NDA) Approvals fo
Read more →ALDXAldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease Top-Line Results from First of Two Planned Clinical Trials Based on Tear RASP Levels Expected by the End of 2020 New Drug Ap
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease LEXINGTON, Mass., July 7, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the pot
Read more →ALDXAldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease LEXINGTON, Mass., June 4, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology comp
Read more →ALDXAldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs ADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs Lexington, Mass., May 7, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with th
Read more →ALDXAldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial and Clinical Development Plans for ADX-629 LEXINGTON, Mass., April 14, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with
Read more →ALDXAldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones INVIGORATE Phase 3 Trial of Reproxalap in Allergic Conjunctivitis Expected to be Completed in Second H
Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Lexington, Mass., March 12, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to
Read more →ALDXAldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day Primary Endpoint of Symptom Control Achieved in Phase 2 Dry Eye Disease Formulation Clinical Trial Sta
Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day LEXINGTON, Mass., Feb. 24, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today will host the 2020 Research & Development Day (R&D Day) with investor
Read more →ALDXAldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors Addition of 35-Year Pharmaceutical Industry Veteran Augments Board s Business Development and Commercial Strategy Expertise Lexington, Ma
Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors Addition of 35-Year Pharmaceutical Industry Veteran Augments Board s Business Development and Commercial Strategy Expertise Lexington, Mass., January 14, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldey
Read more →ALDXAldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Primary objective of RENEW Part 1 achieved: Induction-maintenance dosing regimen of topical ocular r
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease LEXINGTON, Mass., December 3, 2019 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing nex
Read more →ALDXAldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Compl
Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated LEXINGTON, Mass., November 7, 2019 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medici
Read more →ALDXAldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy Lexington, Mass.
Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy Lexington, Mass., September 24, 2019 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that the U.S. Food and Drug Administration (FDA) ha
Read more →ALDXAldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019 Meeting with FD
Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update LEXINGTON, Mass. (BUSINESS WIRE) Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines
Read more →ALDXAldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis Initiated Adaptive Phase 3 RENEW Trial i
Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update LEXINGTON, Mass., May 9, 2019 /PRNewswire/ Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation me
Read more →ALDXAldeyra Therapeutics Announces Year-End 2018 Financial Results Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Dise
Aldeyra Therapeutics Announces Year-End 2018 Financial Results LEXINGTON, Mass., March 8, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives o
Read more →ALDXAldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Diseas
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Resul
Read more →ALDXAldeyra Therapeutics Announces Third Quarter 2018 Financial Results Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-S
Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-Sponsored Phase 1/2 Clinical Trial of ADX-1612 in Malignant
Read more →ALDXAldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19 th World Conference on Lung Cancer 61% Partial
Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer 61% Partial Response Rate of ADX-1612 in Combination with LEXINGTON,
Read more →ALDXAldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter
Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018 Clinical Results from Investigator-Sponsored Trial o
Read more →ALDXAldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer
Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer LEXINGTON, Mass., July 31, 2018 (PRNewswire) Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients wi
Read more →ALDXAldeyra Therapeutics Announces First Quarter 2018 Financial Results
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results LEXINGTON, Mass., May 15, 2018 /PRNewswire/ Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with
Read more →ALDXAldeyra Therapeutics Announces Year End 2017 Financial Results
Aldeyra Therapeutics Announces Year End 2017 Financial Results LEXINGTON, Mass., Mar. 29, 2018 /PRNewswire/ Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inf
Read more →ALDXAldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory LEXINGTON, Mass., Feb. 27, 2018 /PRNewswire/ Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to dev
Read more →ALDXAldeyra Therapeutics Announces Third Quarter 2017 Financial Results
Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results LEXINGTON, Mass., November 9, 2017 /PRNewswire/ Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ( Aldeyra or the Company ), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of me
Read more →ALDXAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares LEXINGTON, Mass., September 21, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to
Read more →ALDXAldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock LEXINGTON, Mass., September 19, 2017 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and ot
Read more →ALDXAldeyra Therapeutics Announces Second Quarter 2017 Financial Results Lexington, MA
Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results Lexington, MA, August 8, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra or the Company), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other
Read more →ALDXAldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, presented the results of a randomized,
Read more →ALDXAldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results Significant Platform Advancement Across Four Clinical Programs Details Provided on 2017 and 2018 Catalysts Lexington, MA
Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results Significant Platform Advancement Across Four Clinical Programs Details Provided on 2017 and 2018 Catalysts Lexington, MA, May 15, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Al
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
LEXINGTON, MA--(Marketwired - May 8, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will provide a corpo
Read more →ALDXAldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
LEXINGTON, MA--(Marketwired - Apr 27, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endo
Read more →ALDXAldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
LEXINGTON, MA--(Marketwired - Apr 18, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endo
Read more →ALDXAldeyra Therapeutics Reports Full Year 2016 Financial Results Lexington, MA
Aldeyra Therapeutics Reports Full Year 2016 Financial Results Lexington, MA, March 30, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the year ended December 31
Read more →ALDXAldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
LEXINGTON, MA--(Marketwired - Feb 28, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra,
Read more →ALDXAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares LEXINGTON, Mass., February 17, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the
Read more →ALDXAldeyra Therapeutics, Inc. Prices Public Offering of Common Stock
Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock LEXINGTON, Mass., February 14, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the p
Read more →ALDXAldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock
Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock LEXINGTON, Mass., February 13, 2017 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced tha
Read more →ALDXAldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
LEXINGTON, MA--(Marketwired - Feb 7, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase 2b clinical t
Read more →ALDXAldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day
LEXINGTON, MA--(Marketwired - Feb 6, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra,
Read more →ALDXAldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs Noninfectious Anterior Uveitis: Enrollment of first-ever vehicle-controlled Phase 3 clinical trial is expected to begin in the second quarte
Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today provided an update on its Phase 3 cl
Read more →ALDXAldeyra Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
LEXINGTON, MA--(Marketwired - Nov 22, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra,
Read more →ALDXAldeyra Therapeutics Announces Third Quarter 2016 Financial Results On Track to Initiate Two Phase II and Two Phase III Trials in 2017 LEXINGTON, MA (Marketwired) 11/14/2016 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Ald
Aldeyra Therapeutics Announces Third Quarter 2016 Financial Results On Track to Initiate Two Phase II and Two Phase III Trials in 2017 LEXINGTON, MA (Marketwired) 11/14/2016 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development
Read more →ALDXAldeyra Therapeutics to Present at the Stifel 2016 Healthcare Conference
LEXINGTON, MA--(Marketwired - Nov 9, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra,
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results
LEXINGTON, MA--(Marketwired - Nov 8, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the third quarter ended Sep
Read more →ALDXAldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
LEXINGTON, MA--(Marketwired - Nov 7, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced an upcoming poster presentation at the 2016 American College of
Read more →ALDXAldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
LEXINGTON, MA--(Marketwired - Sep 26, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) First-Ever Vehicle-Controlled Phase III Clinical Trial in Noninfectious Anterior Uveitis First-Ever Phase III Clinical Trial in Sj gren-Larsson Syndrome Allergic Conjunctivitis Phase IIb Cl
Read more →ALDXDisclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of Section 21E of the Securities Exchange
A Novel Pharmaceutical Platform Focused on Inflammation and Rare Inborn Errors of Metabolism Research and Development Day September 26, 2016 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation
Read more →ALDXAldeyra Therapeutics Appoints Richard H. Douglas to Its Board of Directors LEXINGTON, MA -- (Marketwired) 9/14/2016 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the developme
Aldeyra Therapeutics Appoints Richard H. Douglas to Its Board of Directors LEXINGTON, MA -- (Marketwired) 9/14/2016 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, tod
Read more →ALDXAldeyra Therapeutics Announces 2016 Research and Development Day
LEXINGTON, MA--(Marketwired - Sep 9, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the
Read more →ALDXAldeyra Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update Three Positive Clinical Trials Announced in 2016 LEXINGTON, MA (Marketwired) 8/10/2016 Aldeyra Therapeutics, Inc. (NASDAQ
Aldeyra Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update Three Positive Clinical Trials Announced in 2016 LEXINGTON, MA (Marketwired) 8/10/2016 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the
Read more →ALDXDisclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyr
Results of a randomized, double-blind, vehicle-controlled clinical trial of topical dermatologic NS2 in patients with ichthyosis due to Sj gren-Larsson Syndrome August 9, 2016 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking st
Read more →ALDXAldeyra Therapeutics Schedules Conference Call to Present Results of a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial in Sjogren-Larsson Syndrome
LEXINGTON, MA--(Marketwired - Aug 8, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that, on Tuesday, August 9, 2016, prior to the market open, it
Read more →ALDXAldeyra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
LEXINGTON, MA--(Marketwired - Aug 4, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra,
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2016 Financial and Operating Updates
LEXINGTON, MA--(Marketwired - Aug 3, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the second quarter
Read more →ALDXAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter Overallotment Option
LEXINGTON, MA--(Marketwired - Jun 1, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public off
Read more →ALDXAldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects with Noninfectious Anterior Uveitis Company to Provide Corporate Update and First Quarter Financial Results Announcement of the Sec
Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects with Noninfectious Anterior Uveitis Company to Provide Corporate Update and First Quarter Financial Results Announcement of the Second Positive Phase II Clinical Trial of NS2 in 2016 NS2
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for First Quarter 2016 Financial and Operating Updates
LEXINGTON, MA--(Marketwired - May 5, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the first quarter
Read more →ALDXDisclaimers and Forward Looking Statements 2 This presentation contains forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Alde
Phase II study in SSADH patients Metabolites and clinical endpoints Progress to longer duration dosing evaluating disease modification Hope for the Future 12 In 2016, we expect to build on our accomplishments from last year by initiating clinical development of aldehyde traps tha
Read more →ALDXAldeyra Therapeutics Reports Full Year 2015 Financial Results Lexington, MA
Aldeyra Therapeutics Reports Full Year 2015 Financial Results Lexington, MA, March 30, 2016 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced its financial r
Read more →ALDXAldeyra Therapeutics to Present at the 2016 SSADH Symposium
LEXINGTON, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that David J. Clark, M.D., Chief Medical Officer of Alde
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2015 Financial Results
LEXINGTON, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the fourth
Read more →ALDXAldeyra Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
LEXINGTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Al
Read more →ALDXAldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis
NS2 Demonstrates Statistically Significant and Sustained Clinical Effects Data Suggest Aldehyde Trapping as Novel Approach for the Treatment of Inflammatory Diseases Conference Call to Be Held Today at 8:00 am ET LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Aldeyra Ther
Read more →ALDXAldeyra Therapeutics Appoints Mary Taylor, MPH as Senior Vice President, Regulatory Affairs
LEXINGTON, Mass., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Mary E. Taylor, MPH has joined the Company as its Se
Read more →ALDXAldeyra Therapeutics Appoints David J. Clark, M.D. as Chief Medical Officer
LEXINGTON, Mass., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that David J. Clark, M.D. has joined the Company as its C
Read more →ALDXAldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis
LEXINGTON, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra’s P
Read more →ALDXAldeyra Therapeutics to Present at the 27th Annual Piper Jaffray Healthcare Conference
LEXINGTON, Mass., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Ald
Read more →ALDXAldeyra Therapeutics Reports Third Quarter and Year to Date 2015 Financial and Operating Results Lexington, MA
Aldeyra Therapeutics Reports Third Quarter and Year to Date 2015 Financial and Operating Results Lexington, MA, November 12, 2015 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to alde
Read more →ALDXAldeyra Therapeutics to Present at the Stifel 2015 Healthcare Conference
LEXINGTON, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Ald
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2015 Financial and Operating Results
LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial and operating results for
Read more →ALDXAldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial
LEXINGTON, Mass., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase IIa cl
Read more →ALDXAldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics (ASHG) Annual Meeting
LEXINGTON, Mass., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on the potential of its lead product
Read more →ALDXAldeyra Therapeutics Reports Second Quarter and Year to Date 2015 Financial Results and Provides Development Updates
Aldeyra Therapeutics Reports Second Quarter and Year to Date 2015 Financial Results and Provides LEXINGTON, Mass., August 11, 2015 Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to fre
Read more →ALDXAldeyra Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
LEXINGTON, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results
LEXINGTON, Mass., July 28, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the sec
Read more →ALDXAldeyra Therapeutics to Ring the Nasdaq Stock Market Closing Bell
LEXINGTON, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will visit the Nasdaq MarketSite in Times Sq
Read more →ALDXAldeyra Therapeutics, Inc. (Nasdaq: ALDX) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, June 26, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Todd Bra
Read more →ALDXAldeyra Therapeutics Announces Closing of Common Stock Offering
LEXINGTON, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that the underwriters for its recently completed unde
Read more →ALDXAldeyra Therapeutics Reports First Quarter 2015 Financial and Operating Results Initiated Two Phase II Clinical Trials and Secured $9.0 Million In Net Proceeds Through Two Private Placements In Q1 Follow-On Public Offeri
Aldeyra Therapeutics Reports First Quarter 2015 Financial and Operating Results Initiated Two Phase II Clinical Trials and Secured $9.0 Million In Net Proceeds Through Two Private Placements In Q1 Follow-On Public Offering Resulting in $18.8 Million In Net Proceeds Expected to
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for First Quarter 2015 Financial Results
LEXINGTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the firs
Read more →ALDXAldeyra Therapeutics Announces Pricing of Follow-On Public Offering of Common Stock
LEXINGTON, Mass., May 8, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the pricing of its follow-on public offering of 2,700,
Read more →ALDXAldeyra Therapeutics Launches Proposed Follow-on Public Offering of Common Stock
LEXINGTON, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has commenced a proposed follow-on public offe
Read more →ALDXAldeyra Therapeutics Abstract Accepted for Presentation at the 2015 Multinational Association of Supportive Care in Cancer - International Society of Oral Oncology (MASCC-ISOO) Annual Meeting
LEXINGTON, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2,
Read more →ALDXAldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial
LEXINGTON, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has enrolled the first patient in its Phase
Read more →ALDXAldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial
LEXINGTON, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has opened enrollment for its Phase II clin
Read more →ALDXAldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial
LEXINGTON, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has enrolled the first patient in its Phase
Read more →ALDXAldeyra Therapeutics Reports Full Year 2014 Financial Results Lexington, MA
Aldeyra Therapeutics Reports Full Year 2014 Financial Results Lexington, MA, March 19, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its finan
Read more →ALDXAldeyra Therapeutics Opens Enrollment in Sj gren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol Lexington, MA
Aldeyra Therapeutics Opens Enrollment in Sj gren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol Lexington, MA, March 17, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the develo
Read more →ALDXAldeyra Therapeutics Opens Enrollment in Sjogren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol
LEXINGTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has opened enrollment for its Phase II clin
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results
LEXINGTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the fo
Read more →ALDXXXXXX X Forward Looking Statements This presentation contains forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plan
(1) 2015 Medical Conferences 23 Conference Date Location Data February 20 24 Houston, TX Cytokine Reduction, Contact Dermatitis, and Allergic Dermatitis March 28 31 Salt Lake, UT SLS Lipid Protection May 3 7 Denver, CO Ocular Inflammation and Ocular Fibrosis Significant data to b
Read more →ALDXAldeyra Therapeutics Provides Update on NS2 Clinical Program
LEXINGTON, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today provided an update on its planned clinical trial programs in n
Read more →ALDXAldeyra Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference
LEXINGTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO o
Read more →ALDXAldeyra Therapeutics Abstracts Accepted for Presentation at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology
LEXINGTON, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, h
Read more →ALDXAldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting
LEXINGTON, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on the potential of its lead product
Read more →ALDXAldeyra Therapeutics to Participate in Canaccord Genuity Rare Disease, BioPharma One-on-One Day
LEXINGTON, Mass., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and Chief
Read more →ALDXAldeyra Therapeutics Completes $2.0 Million Private Placement Lexington, MA
Aldeyra Therapeutics Completes $2.0 Million Private Placement Lexington, MA, January 22, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the clo
Read more →ALDXAldeyra Therapeutics Announces $2.0 Million Private Placement Lexington, MA
Aldeyra Therapeutics Announces $2.0 Million Private Placement Lexington, MA, January 20, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it
Read more →ALDXAldeyra Therapeutics Completes $7.79 Million Private Placement Lexington, MA
Aldeyra Therapeutics Completes $7.79 Million Private Placement Lexington, MA, January 15, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the cl
Read more →ALDXAldeyra Therapeutics Announces $7.79 Million Private Placement Lexington, MA
Aldeyra Therapeutics Announces $7.79 Million Private Placement Lexington, MA, January 13, 2015 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that i
Read more →ALDXAldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome
LEXINGTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that an Investigational New Drug application (IND) to
Read more →ALDXAldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis Lexington, MA
Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis Lexington, MA, December 18, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today
Read more →ALDXAldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting
LEXINGTON, Mass., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel anti-inflammatory data on its lead produc
Read more →ALDXAldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients
LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organizati
Read more →ALDXAldeyra Therapeutics to Present at the Therapeutic Area Partnerships Meeting
LEXINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO o
Read more →ALDXAldeyra Therapeutics Reports Third Quarter and Year to Date 2014 Financial Results Lexington, MA
Aldeyra Therapeutics Reports Third Quarter and Year to Date 2014 Financial Results Lexington, MA, November 10, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, t
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
BURLINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the thi
Read more →ALDXAldeyra Therapeutics to Present at Upcoming Investor Conferences
BURLINGTON, Mass., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO
Read more →ALDXForward Looking Statements This presentation includes statements contains forward looking statements that involve risks and uncertainties. In some cases, you can identify forward looking statements by terms such as may,
Data as of 8/26/14 (1) INDs anticipated by end of 2014, pending FDA review, among other contingencies. (1) Company Stage Diseases in Phase II or III Clinical Trials Valuation Aldeyra Therapeutics (ALDX) Phase II 2 $23M Bluebird Bio (BLUE) Phase II 2 $1.1B Sarepta Therapeutics (SR
Read more →ALDXAldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials Burlington, MA
Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials Burlington, MA, September 2, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes
Read more →ALDXAldeyra Therapeutics Reports Second Quarter 2014 Financial Results Burlington, MA
Aldeyra Therapeutics Reports Second Quarter 2014 Financial Results Burlington, MA, August 4, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, toda
Read more →ALDXAldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
BURLINGTON, Mass., July 23, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced that it will issue its financial resu
Read more →ALDXALDEYRA THERAPEUTICS TO JOIN RUSSELL MICROCAP INDEX Burlington, MA
ALDEYRA THERAPEUTICS TO JOIN RUSSELL MICROCAP INDEX Burlington, MA, June 26, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, announced today that it will be add
Read more →ALDXALDEYRA THERAPEUTICS APPOINTS STEPHEN TULIPANO CHIEF FINANCIAL OFFICER Burlington, MA
ALDEYRA THERAPEUTICS APPOINTS STEPHEN TULIPANO CHIEF FINANCIAL OFFICER Burlington, MA, June 19, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced
Read more →ALDXAldeyra Therapeutics Reports First Quarter 2014 Financial Results Burlington, MA
Aldeyra Therapeutics Reports First Quarter 2014 Financial Results Burlington, MA, June 11, 2014 Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its f
Read more →ALDXNS2, a novel aldehyde trap, decreases aldehyde levels in dry skin and eye models Scott L. Young 1 , Todd C. Brady 1 , Eduardo Perez 2 , Maxwell Stock 2 , Jose R. Fernandez 2 1 Aldeyra Therapeutics, Inc., Burlington, MA 2
By trapping aldehydes, NS2 may protect skin and eye tissue from chronic inflammation caused by aldehydes that are generated in dry conditions, and in addition may protect lipids that are critical in preserving moisture in skin and eye. Thus, NS2 represents a potential novel compo
Read more →ALDXAldeyra Therapeutics' Data on Lead Candidate NS2 to be Presented at Society for Investigative Dermatology 2014 Annual Meeting
BURLINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that new data supporting its lead product candidate,
Read more →ALDXAldeyra Therapeutics Announces Closing of Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced initial publi
Read more →ALDXAldeyra Therapeutics Prices Initial Public Offering of 1,500,000 Shares of Common Stock
BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics ("Aldeyra"), a biotechnology company focused on the development of products to treat diseases where free aldehydes are thought to be important to the pathology, today announced the pricing of its initial publ
Read more →Competitive Position
How ALDX ranks across every disease it competes inCompetitive Position is a premium feature
See how ALDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial